China's first homegrown EGFR inhibitor to be provided free to some patients
This article was originally published in Scrip
Zhejiang Beta Pharma has been making waves in China's pharma industry since last August when it launched Conmana (icotinib), the first patented, targeted small-molecule drug for non-small cell lung cancer (NSCLC) to be developed in the country.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.